A citation-based method for searching scientific literature

Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue, Dong Soon Kim, Martin Kolb, Andrew G Nicholson, Paul W Noble, Moisés Selman, Hiroyuki Taniguchi, Michèle Brun, Florence Le Maulf, Mannaïg Girard, Susanne Stowasser, Rozsa Schlenker-Herceg, Bernd Disse, Harold R Collard. N Engl J Med 2014
Times Cited: 2190







List of co-cited articles
630 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
53

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
36

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
522
33

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
26

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
24

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
538
20

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
663
16

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
461
14

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
14

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
923
13

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
12

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
379
12

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
223
11

Spectrum of Fibrotic Lung Diseases.
Marlies Wijsenbeek, Vincent Cottin. N Engl J Med 2020
96
10

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
626
10

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
187
10

The natural history of progressive fibrosing interstitial lung diseases.
Kevin K Brown, Fernando J Martinez, Simon L F Walsh, Victor J Thannickal, Antje Prasse, Rozsa Schlenker-Herceg, Rainer-Georg Goeldner, Emmanuelle Clerisme-Beaty, Kay Tetzlaff, Vincent Cottin,[...]. Eur Respir J 2020
65
15

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
588
9

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis.
Taylor S Adams, Jonas C Schupp, Sergio Poli, Ehab A Ayaub, Nir Neumark, Farida Ahangari, Sarah G Chu, Benjamin A Raby, Giuseppe DeIuliis, Michael Januszyk,[...]. Sci Adv 2020
175
9

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
416
9

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Athol U Wells, Kevin R Flaherty, Kevin K Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A Wuyts, Susanne Stowasser,[...]. Lancet Respir Med 2020
135
9

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
Jürgen Behr, Antje Prasse, Hubert Wirtz, Dirk Koschel, David Pittrow, Matthias Held, Jens Klotsche, Stefan Andreas, Martin Claussen, Christian Grohé,[...]. Eur Respir J 2020
39
23

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
323
9

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Jürgen Behr, Antje Prasse, Michael Kreuter, Johannes Johow, Klaus F Rabe, Francesco Bonella, Reiner Bonnet, Christian Grohe, Matthias Held, Heinrike Wilkens,[...]. Lancet Respir Med 2021
51
17

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
573
8

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Lutz Wollin, Jörg H W Distler, Elizabeth F Redente, David W H Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M Maher, Martin Kolb. Eur Respir J 2019
85
9

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Andreas Guenther, Ekaterina Krauss, Silke Tello, Jasmin Wagner, Bettina Paul, Stefan Kuhn, Olga Maurer, Sabine Heinemann, Ulrich Costabel, María Asunción Nieto Barbero,[...]. Respir Res 2018
124
8

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
7

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Vincent Cottin, Nikhil A Hirani, David L Hotchkin, Anoop M Nambiar, Takashi Ogura, María Otaola, Dirk Skowasch, Jong Sun Park, Hataya K Poonyagariyagorn, Wim Wuyts,[...]. Eur Respir Rev 2018
162
7

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Ganesh Raghu, Juergen Behr, Kevin K Brown, Jim J Egan, Steven M Kawut, Kevin R Flaherty, Fernando J Martinez, Steven D Nathan, Athol U Wells, Harold R Collard,[...]. Ann Intern Med 2013
298
7

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
914
7

What's in a name? That which we call IPF, by any other name would act the same.
Athol U Wells, Kevin K Brown, Kevin R Flaherty, Martin Kolb, Victor J Thannickal. Eur Respir J 2018
135
7

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel,[...]. Eur Respir J 2021
37
18

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Craig E Daniels, Joseph A Lasky, Andrew H Limper, Kathleen Mieras, Edith Gabor, Darrell R Schroeder. Am J Respir Crit Care Med 2010
266
7

Idiopathic pulmonary fibrosis.
Fernando J Martinez, Harold R Collard, Annie Pardo, Ganesh Raghu, Luca Richeldi, Moises Selman, Jeffrey J Swigris, Hiroyuki Taniguchi, Athol U Wells. Nat Rev Dis Primers 2017
368
6

Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.
Boris Duchemann, Isabella Annesi-Maesano, Camille Jacobe de Naurois, Shreosi Sanyal, Pierre-Yves Brillet, Michel Brauner, Marianne Kambouchner, Sophie Huynh, Jean Marc Naccache, Raphael Borie,[...]. Eur Respir J 2017
109
6

A common MUC5B promoter polymorphism and pulmonary fibrosis.
Max A Seibold, Anastasia L Wise, Marcy C Speer, Mark P Steele, Kevin K Brown, James E Loyd, Tasha E Fingerlin, Weiming Zhang, Gunnar Gudmundsson, Steve D Groshong,[...]. N Engl J Med 2011
643
6

Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Christopher J Ryerson, Jeffrey L Myers, Michael Kreuter, Martina Vasakova, Elena Bargagli, Jonathan H Chung, Bridget F Collins, Elisabeth Bendstrup,[...]. Am J Respir Crit Care Med 2020
173
6

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.
Joshua J Solomon, Jonathan H Chung, Gregory P Cosgrove, M Kristen Demoruelle, Evans R Fernandez-Perez, Aryeh Fischer, Stephen K Frankel, Stephen B Hobbs, Tristan J Huie, Jill Ketzer,[...]. Eur Respir J 2016
156
6

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
Peter M George, Paolo Spagnolo, Michael Kreuter, Goksel Altinisik, Martina Bonifazi, Fernando J Martinez, Philip L Molyneaux, Elisabetta A Renzoni, Luca Richeldi, Sara Tomassetti,[...]. Lancet Respir Med 2020
73
8

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
223
6

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
Peter M George, Athol U Wells, R Gisli Jenkins. Lancet Respir Med 2020
414
6

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.
Andrew M Tager, Peter LaCamera, Barry S Shea, Gabriele S Campanella, Moisés Selman, Zhenwen Zhao, Vasiliy Polosukhin, John Wain, Banu A Karimi-Shah, Nancy D Kim,[...]. Nat Med 2008
512
6

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Aryeh Fischer, Katerina M Antoniou, Kevin K Brown, Jacques Cadranel, Tamera J Corte, Roland M du Bois, Joyce S Lee, Kevin O Leslie, David A Lynch, Eric L Matteson,[...]. Eur Respir J 2015
482
5

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
84
5

Standardisation of spirometry.
M R Miller, J Hankinson, V Brusasco, F Burgos, R Casaburi, A Coates, R Crapo, P Enright, C P M van der Grinten, P Gustafsson,[...]. Eur Respir J 2005
5

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia.
Xiaoyu Han, Yanqing Fan, Osamah Alwalid, Na Li, Xi Jia, Mei Yuan, Yumin Li, Yukun Cao, Jin Gu, Hanping Wu,[...]. Radiology 2021
150
5

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
Talmadge E King, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Phil Hormel, Lisa Lancaster, Paul W Noble, Steven A Sahn, Javier Szwarcberg, Michiel Thomeer,[...]. Lancet 2009
350
5

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
966
5

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
Scott M Palmer, Laurie Snyder, Jamie L Todd, Benjamin Soule, Rose Christian, Kevin Anstrom, Yi Luo, Robert Gagnon, Glenn Rosen. Chest 2018
72
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.